Arwin Ridder

2.4k total citations
30 papers, 1.7k citations indexed

About

Arwin Ridder is a scholar working on Urology, Rheumatology and Epidemiology. According to data from OpenAlex, Arwin Ridder has authored 30 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Urology, 19 papers in Rheumatology and 16 papers in Epidemiology. Recurrent topics in Arwin Ridder's work include Urinary Bladder and Prostate Research (25 papers), Pelvic floor disorders treatments (19 papers) and Urinary Tract Infections Management (16 papers). Arwin Ridder is often cited by papers focused on Urinary Bladder and Prostate Research (25 papers), Pelvic floor disorders treatments (19 papers) and Urinary Tract Infections Management (16 papers). Arwin Ridder collaborates with scholars based in Netherlands, United Kingdom and United States. Arwin Ridder's co-authors include Christopher R. Chapple, Moses Huang, L. Cardozo, Tomasz Rechberger, Asha Paireddy, Karel Everaert, Con Kelleher, Ted Drogendijk, С Х Аль-Шукри and Paul Abrams and has published in prestigious journals such as The Journal of Urology, European Urology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Arwin Ridder

30 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Arwin Ridder Netherlands	18	1.5k	1.3k	1.0k	158	97	30	1.7k
Ted Drogendijk Netherlands	13	1.4k 0.9×	1.2k 0.9×	916 0.9×	165 1.0×	94 1.0×	22	1.6k
Paul Siami United States	16	1.3k 0.8×	665 0.5×	290 0.3×	151 1.0×	102 1.1×	30	1.5k
Jay M. Young United States	16	712 0.5×	172 0.1×	45 0.0×	62 0.4×	91 0.9×	22	1.3k
Frederick H. Meyers United States	15	420 0.3×	208 0.2×	73 0.1×	134 0.8×	44 0.5×	40	866
K‐E. Andersson Sweden	8	208 0.1×	104 0.1×	69 0.1×	40 0.3×	46 0.5×	10	444
Ahmet Gökçe Türkiye	19	245 0.2×	64 0.1×	15 0.0×	252 1.6×	33 0.3×	66	909
Emre Can Polat Türkiye	16	137 0.1×	85 0.1×	32 0.0×	124 0.8×	67 0.7×	58	723
Lars‐Göran Allgén Sweden	12	87 0.1×	51 0.0×	33 0.0×	116 0.7×	16 0.2×	36	508
Paul Kotey United States	11	206 0.1×	20 0.0×	88 0.1×	226 1.4×	432 4.5×	17	813
Hakkı Perk Türkiye	13	87 0.1×	66 0.1×	40 0.0×	93 0.6×	17 0.2×	28	455

Countries citing papers authored by Arwin Ridder

Since Specialization

Citations

This map shows the geographic impact of Arwin Ridder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arwin Ridder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arwin Ridder more than expected).

Fields of papers citing papers by Arwin Ridder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arwin Ridder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arwin Ridder. The network helps show where Arwin Ridder may publish in the future.

Co-authorship network of co-authors of Arwin Ridder

This figure shows the co-authorship network connecting the top 25 collaborators of Arwin Ridder. A scholar is included among the top collaborators of Arwin Ridder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arwin Ridder. Arwin Ridder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

White, William B., Christopher R. Chapple, Christian Gratzke, et al.. (2018). Cardiovascular Safety of the β₃‐Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial. The Journal of Clinical Pharmacology. 58(8). 1084–1091. 17 indexed citations

Gratzke, Christian, Rob van Maanen, Christopher R. Chapple, et al.. (2018). Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). European Urology. 74(4). 501–509. 67 indexed citations

Weber, Michael A., Christopher R. Chapple, Christian Gratzke, et al.. (2018). A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects. Blood Pressure Monitoring. 23(3). 153–163. 10 indexed citations

Herschorn, Sender, Christopher R. Chapple, Paul Abrams, et al.. (2017). Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder ( SYNERGY study). British Journal of Urology. 120(4). 562–575. 108 indexed citations

Gratzke, Christian, Rob van Maanen, Christopher R. Chapple, et al.. (2017). PNFLBA-09 LONG-TERM COMBINATION TREATMENT WITH SOLIFENACIN AND MIRABEGRON IS EFFECTIVE AND WELL TOLERATED IN PATIENTS WITH OVERACTIVE BLADDER. The Journal of Urology. 197(4S). 1 indexed citations

Abrams, Paul, Con Kelleher, David Staskin, et al.. (2016). Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology. 35(5). 827–838. 37 indexed citations

Abrams, Paul, Jean Paty, Reynaldo Martina, et al.. (2015). Electronic bladder diaries of differing duration versus a paper diary for data collection in overactive bladder. Neurourology and Urodynamics. 35(6). 743–749. 22 indexed citations

Newgreen, Donald, et al.. (2015). A quantitative benefit–risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder. Clinical Pharmacology & Therapeutics. 99(4). 442–451. 7 indexed citations

Abrams, Paul, Con Kelleher, David Staskin, et al.. (2014). Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony). European Urology. 67(3). 577–588. 163 indexed citations

10.

Chapple, Christopher R., G. Amarenco, Karel Everaert, et al.. (2013). A proof‐of‐concept study: Mirabegron, a new therapy for overactive bladder. Neurourology and Urodynamics. 32(8). 1116–1122. 79 indexed citations

11.

Chapple, Christopher R., Vladimír Dvořák, Philip Van Kerrebroeck, et al.. (2013). A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal. 24(9). 1447–1458. 107 indexed citations

12.

Abrams, Paul, Con Kelleher, David Staskin, et al.. (2013). 1958 COMBINATION TREATMENT WITH MIRABEGRON AND SOLIFENACIN IN PATIENTS WITH OVERACTIVE BLADDER (OAB) - EFFICACY RESULTS FROM A PHASE 2 STUDY (SYMPHONY). The Journal of Urology. 189(4S). 6 indexed citations

13.

Cardozo, Linda, David Castro‐Díaz, Marc Gittelman, Arwin Ridder, & Moses Huang. (2006). Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. International Urogynecology Journal. 17(5). 512–519. 32 indexed citations

14.

Haab, F., L. Cardozo, Christopher R. Chapple, & Arwin Ridder. (2004). Long-Term Open-Label Solifenacin Treatment Associated with Persistence with Therapy in Patients with Overactive Bladder Syndrome. European Urology. 47(3). 376–384. 113 indexed citations

15.

Chapple, Christopher R., Tomasz Rechberger, С Х Аль-Шукри, et al.. (2004). Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. British Journal of Urology. 93(3). 303–310. 280 indexed citations

16.

Kelleher, Con, Linda Cardozo, Christopher R. Chapple, François Haab, & Arwin Ridder. (2004). Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. British Journal of Urology. 95(1). 81–85. 94 indexed citations

17.

Chapple, Christopher R., Ulrich Jonas, M. Chancellor, & Arwin Ridder. (2004). 508 New antimuscarinic agent, solifenacin succinate, reduces urgency episodes in overactive bladder: An analysis of over 3000 patients. European Urology Supplements. 3(2). 129–129. 7 indexed citations

18.

Chapple, Christopher R., Pedro Arañó, Jackie Bosch, et al.. (2003). Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo‐ and tolterodine‐controlled phase 2 dose‐finding study. British Journal of Urology. 93(1). 71–77. 134 indexed citations

19.

Chapple, Christopher R., et al.. (2002). YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a european placebo- and tolterodinge-conrolled, phase-II, dose-finding study. Neurourology and Urodynamics. 21(4). 381–382. 10 indexed citations

20.

Schanstra, Joost P., Arwin Ridder, Jaap Kingma, & Dick B. Janssen. (1997). Influence of mutations of Val226 on the catalytic rate of haloalkane dehalogenase. Protein Engineering Design and Selection. 10(1). 53–61. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact